Amoéba S.A. (EPA:ALMIB)

Market Cap	57.93M +7.1%
Revenue (ttm)	695.45K +15.6%
Net Income	-8.30M
EPS	-0.14
Shares Out	68.89M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	175,059
Average Volume	568,377
Open	0.8380
Previous Close	0.8560
Day's Range	0.8350 - 0.8540
52-Week Range	0.7800 - 1.4440
Beta	0.20
RSI	39.04
Earnings Date	Apr 17, 2026

About Amoéba

Amoéba S.A. develops biological products and services for the treatment of microbiological risk in the sectors of water, health, and plant protection in France. The company has developed technology to treat water, surfaces, and chronic wounds that uses the natural biocidal capacity of the living amoeba Willaertia magna C2c Maky; and agriculture biocontrol technology for the treatment of phytopathogenic microorganisms using the lysed. Amoéba S.A. was incorporated in 2010 and is based in Chassieu, France.

• Industry: Agricultural Inputs
• Sector: Materials
• Founded: 2010
• Employees: 20
• Stock Exchange: Euronext Paris
• Ticker Symbol: ALMIB

Financial Performance

In 2025, Amoéba's revenue was 695,449, an increase of 15.60% compared to the previous year's 601,600. Losses were -8.30 million, 26.0% more than in 2024.